Developing new anti-cancer medicines

April 11, 2014
Developing new anti-cancer medicines

The prospect of four new cancer medicines becoming a reality for patients has taken a huge step forward with the announcement of a £34M investment by a European private biotech company in University research.

ProTide is a platform developed by Professor Chris McGuigan and his team at Cardiff University's School of Pharmacy and Pharmaceutical Sciences. ProTides are specifically designed to bypass key cell resistance pathways that limit the efficacy of so many of today's .

Edinburgh based , NuCana, has announced a new £34M to develop its portfolio of anti-cancer medicines based on ProTide technology.

The funds will be used to advance and expand the clinical programme for NuCana's lead product, Acelarin, which has shown exceptional results in with a broad range of advanced and progressive cancers that were resistant to all conventional therapies.

Acelarin will be developed initially for patients with pancreatic, biliary, lung and ovarian cancers. In addition, the funding means the company plans to bring a second ProTide (NUC-3373) into the clinic later this year, with two further ProTides scheduled for 2015.

"It is very exciting to watch a new medicine emerge, from a theoretical idea, through chemical synthesis in our laboratory here in Cardiff and now as a new treatment for patients with cancer" according to Professor McGuigan, School of Pharmacy and Pharmaceutical Sciences, who developed the ProTide technology.

"This £34M investment is extremely satisfying and an endorsement of our work with NuCana. Over the last decade this represents the 14th largest private biotech round globally and the largest ever in the UK," he added.

The financing is led by a new investor, US based venture capital firm Sofinnova Ventures. The deal was completed by substantial investments from the largest shareholder, Paris based Sofinnova Partners, alongside other existing major investors Morningside Ventures, Alida Capital International and the Scottish Investment Bank.

NuCana has exclusive worldwide rights to the pioneering ProTide technology in cancer. This technology creates compounds that bypass key resistance mechanisms associated with anti-cancer drugs.

"We are delighted to be working with Chris McGuigan and the team in Cardiff. Over the years we have had a very constructive and productive collaboration with Cardiff University that is now bringing real benefits to patients," said Hugh S Griffith, the Co-Founder and CEO of NuCana.

Professor McGuigan added: "NuCana's ProTide platform has the potential to deliver to patients novel, first-in-class anti-cancer medicines. We are excited to be working with the company's experienced leadership team in the development programme.

"This investment is a real vote of confidence in our research and its application by NuCana. Together this brings real potential for developing new and powerful medicines to treat cancer."

Explore further: World-first clinical trial launches for advanced bowel cancer

Related Stories

World-first clinical trial launches for advanced bowel cancer

April 2, 2014
Patients with advanced bowel cancer are set to benefit from the launch of a revolutionary new clinical trial targeting treatments to their specific cancer type as well as rapidly adapting to include new drugs and new biomarkers ...

Combining Chinese and Western medicine could lead to new cancer treatments

September 28, 2013
Combining traditional forms of Chinese and Western medicine could offer new hope for developing new treatments for liver, lung, colorectal cancers and osteosarcoma of the bones.

Ohio State partners with MedVax to bring a cancer peptide vaccine to patients

March 18, 2014
The Ohio State University, through the Ohio State Innovation Foundation, has signed an exclusive world-wide licensing agreement with MedVax Technologies, Inc., for the licensing of groundbreaking cancer peptide vaccine technologies.

Drug to reverse breast cancer spread in development

January 26, 2014
Researchers at Cardiff University are developing a novel compound known to reverse the spread of malignant breast cancer cells.

Cancer drug RG7813 launches in its first clinical trial

March 28, 2014
(Medical Xpress)—A new cancer drug, based on further development of a discovery originally made by Cancer Research UK, has entered a clinical trial to target a wide range of cancers.

How tumors become resistant to drugs, and how process can be reversed to inhibit cancer growth

April 10, 2014
Researchers at the Hebrew University of Jerusalem's Faculty of Medicine have discovered a process whereby tumor cells become resistant to specific drugs, a finding that could significantly influence how anti-cancer drugs ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.